Averting bloat gives peace of mind
Making the switch from dairying to bull farming several years ago was not the shift all Bruce Kinloch's neighbours would have considered, says Rumensin supplier Elanco.
The takeover, announced last April, follows its purchase of Lohmann Animal Health earlier in 2014. The company says it will be able to offer more product diversity. It now sells nearly 300 brands including therapeutics, vaccines, parasiticides, antimicrobials, surgical, enzymes and food safety.
“Elanco’s acquisition of Novartis Animal Health brings together two strong companies,” says Michele Genini, general manager of Elanco for Australia and New Zealand.
“We will continue to offer the products our customers’ trust, while investing in the development of new solutions to our customers’ greatest unmet needs.”
Genini says Elanco will spend more on R&D. It has 100 product development projects including protecting livestock from disease and parasites, improving animal wellbeing and reducing the environmental footprint of livestock production.
“Elanco is also committed to helping producers around the world produce more food using fewer resources to meet the growing demand for animal protein while protecting the planet and well-being of animals,” Genini says.
“With increased technical services, that combine our analytic and benchmarking tools with on-the-ground support, we’ll be able to spend more time with individual customers seeking innovative solutions that can make a difference in their business.”
He says the complete integration of the businesses will take time, but Elanco will strive to make the transition seamless.
“For the foreseeable future, business will continue in much the same way, including product ordering and customer support. Availability and access to products will continue uninterrupted.”
